Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Aroa Biosurgery Ltd ( (AU:ARX) ).
Aroa Biosurgery Limited announced a change in the interests of its director, John Pinion, as per the latest notice to the ASX. The change involved the lapse of 245,775 options exercisable at $0.75 due to expiry, which impacts the director’s holdings but does not alter the number of fully paid ordinary shares held. This update reflects routine adjustments in director holdings, which are part of standard corporate governance practices, and is unlikely to have significant implications for the company’s operations or market position.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
More about Aroa Biosurgery Ltd
Aroa Biosurgery Limited operates in the biotechnology industry, focusing on the development and commercialization of medical products. The company specializes in regenerative tissue technology, offering products that aid in the healing of complex wounds and soft tissue reconstruction. Aroa Biosurgery targets the healthcare market, providing innovative solutions for surgical and wound care applications.
Average Trading Volume: 233,663
Technical Sentiment Signal: Buy
Current Market Cap: A$203.6M
Find detailed analytics on ARX stock on TipRanks’ Stock Analysis page.